Published in Fibrogenesis Tissue Repair on June 20, 2015
Current perspectives on the immunopathogenesis of systemic sclerosis. Immunotargets Ther (2016) 0.79
Deficient Adipogenesis of Scleroderma Patient and Healthy African American Monocytes. Front Pharmacol (2017) 0.75
Reversal of maladaptive fibrosis and compromised ventricular function in the pressure overloaded heart by a caveolin-1 surrogate peptide. Lab Invest (2017) 0.75
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum (1980) 21.86
Monocyte recruitment during infection and inflammation. Nat Rev Immunol (2011) 7.55
Src family kinases, key regulators of signal transduction. Oncogene (2004) 4.30
CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol (2005) 4.02
Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum (2003) 3.84
Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest (2004) 3.44
Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol (2002) 3.38
Comparison of gene expression profiles between human and mouse monocyte subsets. Blood (2009) 3.15
Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med (2006) 2.92
Scleroderma epidemiology. Rheum Dis Clin North Am (2003) 1.70
Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol (2008) 1.68
Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair (2012) 1.37
Caveolin-1, transforming growth factor-beta receptor internalization, and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol (2008) 1.32
Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheum (2011) 1.31
Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair (2011) 1.26
Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One (2010) 1.25
Pivotal role of CCR1-positive leukocytes in bleomycin-induced lung fibrosis in mice. J Immunol (2000) 1.20
Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum (2008) 1.16
Racial differences in scleroderma among women in Michigan. Arthritis Rheum (1997) 1.10
Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann Rheum Dis (2010) 1.07
Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum (2003) 1.07
Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol (2006) 1.07
Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum (2005) 1.04
Transforming growth factor beta and progression of renal disease. Kidney Int Suppl (2003) 1.04
A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum (2012) 1.02
Systemic sclerosis mortality in the United States: 1979-1998. Eur J Epidemiol (2005) 1.01
Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol (2003) 0.96
Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol (1998) 0.95
Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis. J Rheumatol (2007) 0.94
Soluble E-selectin induces monocyte chemotaxis through Src family tyrosine kinases. J Biol Chem (2001) 0.94
Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum (2006) 0.92
Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease. Am J Physiol Lung Cell Mol Physiol (2014) 0.91
Cross-talk between MCP-3 and TGFbeta promotes fibroblast collagen biosynthesis. Exp Cell Res (2008) 0.91
Interstitial lung disease of systemic sclerosis. Int Rev Immunol (1995) 0.89
Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol (2014) 0.88
Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis. Front Pharmacol (2014) 0.86
Plasminogen activator inhibitor-1 suppresses profibrotic responses in fibroblasts from fibrotic lungs. J Biol Chem (2015) 0.86
Chemokine receptors CCR2 and CX3CR1 regulate skin fibrosis in the mouse model of cytokine-induced systemic sclerosis. J Dermatol Sci (2012) 0.84
Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry. Front Pharmacol (2014) 0.83
Caveolin-1 deficiency may predispose African Americans to systemic sclerosis-related interstitial lung disease. Arthritis Rheumatol (2014) 0.80
Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Ann Rheum Dis (2006) 0.80
Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology (Oxford) (2008) 0.78